Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 14, 2024, at 8:30 a.m. PDT / 11:30 a.m. EDT.
Pascal Touchon, President and CEO, and Dr. Cokey Nguyen, Executive VP and Chief Scientific & Technical Officer, will represent the company. Atara specializes in developing transformative therapies for cancer and autoimmune diseases using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform.
A live webcast of the presentation will be available on the Investors and Media section of atarabio.com, with an archived replay accessible for 30 days following the event.
Atara Biotherapeutics (Nasdaq: ATRA), leader nell'immunoterapia con cellule T, ha annunciato la sua partecipazione alla 44a Conferenza Annuale sulla Crescita di Canaccord Genuity. L'evento è previsto per il 14 agosto 2024, alle 8:30 a.m. PDT / 11:30 a.m. EDT.
Pascal Touchon, Presidente e CEO, e il Dr. Cokey Nguyen, VP Esecutivo e Direttore Scientifico e Tecnico, rappresenteranno l'azienda. Atara si specializza nello sviluppo di terapie trasformative per tumori e malattie autoimmuni utilizzando la sua piattaforma innovativa di cellule T con virus Epstein-Barr (EBV) allogenico.
Una diretta streaming della presentazione sarà disponibile nella sezione Investitori e Media di atarabio.com, con una registrazione archiviata accessibile per 30 giorni dopo l'evento.
Atara Biotherapeutics (Nasdaq: ATRA), líder en inmunoterapia con células T, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El evento está programado para el 14 de agosto de 2024, a las 8:30 a.m. PDT / 11:30 a.m. EDT.
Pascal Touchon, Presidente y CEO, y el Dr. Cokey Nguyen, VP Ejecutivo y Director Científico y Técnico, representarán a la compañía. Atara se especializa en desarrollar terapias transformadoras para cáncer y enfermedades autoinmunes utilizando su innovadora plataforma de células T alogénicas del virus Epstein-Barr (EBV).
Una transmisión en vivo de la presentación estará disponible en la sección de Inversores y Medios de atarabio.com, con una repetición archivada accesible durante 30 días después del evento.
Atara Biotherapeutics (Nasdaq: ATRA)는 T세포 면역요법의 선두주자로서 Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 8월 14일 오전 8:30 PDT / 오전 11:30 EDT에 예정되어 있습니다.
파스칼 투숑(Pascal Touchon) 사장 겸 CEO와 코키 응우옌(Dr. Cokey Nguyen) 책임 부사장 겸 수석 과학 기술 책임자가 회사를 대표합니다. Atara는 자사의 독창적인 EBV(엡스타인 바 바이러스) T세포 플랫폼을 이용하여 암과 자가면역 질환에 대한 전환적 치료법을 개발하는 데 전문성을 가지고 있습니다.
발표의 생중계는 atarabio.com의 투자자 및 미디어 섹션에서 볼 수 있으며, 사건 후 30일 동안 아카이브 재생이 가능합니다.
Atara Biotherapeutics (Nasdaq: ATRA), leader en immunothérapie par cellules T, a annoncé sa participation à la 44e Conférence Annuelle de Croissance de Canaccord Genuity. L'événement est prévu pour le 14 août 2024, à 8h30 PDT / 11h30 EDT.
Pascal Touchon, Président et CEO, et Dr. Cokey Nguyen, VP Exécutif et Directeur Scientifique et Technique, représenteront l'entreprise. Atara se spécialise dans le développement de thérapies transformantes pour le cancer et les maladies auto-immunes grâce à sa plateforme innovante de cellules T allogéniques à virus Epstein-Barr (EBV).
Une diffusion en direct de la présentation sera disponible dans la section Investisseurs et Médias de atarabio.com, avec un replay archivés accessible pendant 30 jours après l'événement.
Atara Biotherapeutics (Nasdaq: ATRA), ein führendes Unternehmen in der T-Zell-Immuntherapie, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity bekannt gegeben. Die Veranstaltung findet am 14. August 2024 um 8:30 Uhr PDT / 11:30 Uhr EDT statt.
Pascal Touchon, Präsident und CEO, sowie Dr. Cokey Nguyen, Executive VP und Chief Scientific & Technical Officer, werden das Unternehmen vertreten. Atara ist auf die Entwicklung transformierender Therapien für Krebs und Autoimmunerkrankungen spezialisiert, indem es seine neuartige allogene EBV (Epstein-Barr-Virus) T-Zell-Plattform nutzt.
Ein Live-Stream der Präsentation wird im Bereich Investoren und Medien auf atarabio.com verfügbar sein, mit einem archivierten Replay, das 30 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807791771/en/
Investor and Media Relations:
Jason Awe, Ph.D.
Head of Corporate Communications & Investor Relations
(805) 217-2287
jawe@atarabio.com
Source: Atara Biotherapeutics, Inc.
FAQ
When is Atara Biotherapeutics (ATRA) participating in the Canaccord Genuity Growth Conference?
Who will be representing Atara Biotherapeutics (ATRA) at the Canaccord Genuity conference?
How can investors access Atara Biotherapeutics' (ATRA) presentation at the Canaccord Genuity conference?
What is the main focus of Atara Biotherapeutics' (ATRA) research and development?
